Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
11 participants
INTERVENTIONAL
2016-02-29
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of this study is also to complete the clinical, immunobiological and morphological analysis of asthma with small airways dysfunction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Biological Therapy.
NCT05792592
Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers
NCT02537691
An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604
NCT06157255
Airway Responsiveness and Inflammation in Adolescent Elite Swimmers: a 3-Year Prospective Follow-up Study
NCT00841425
Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma
NCT02872298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
asthma with proximal or diffuse lung damage
asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.
symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
asthma with small airway prevailing damage
asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.
symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.
symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.
symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age ≥ 18 years
* asthma
* inform consent signed
* affiliated to health insurance
* Maximal Voluntary Ventilation (MMV)\<80%
* MMV / Forced Vital Capacity (FVC)≤70%
* Carbon Monoxide Transfer Coefficient (KcO)\>80%
* Maximal Voluntary Ventilation (MMV)≥80%
* MMV / Vital Capacity(VC)\>70%
* Carbon Monoxide Transfer Coefficient (KcO)\>80%
Exclusion Criteria
* patient participating to other biomedical research
* patient who have participated to other biomedical research within the past 3 months
* patient refusing to sign the inform consent
* Patient who stopped smoking since less than 12 months
* Pathological state related to obstructive distal airway damage
* Broncho-pulmonary infectious disease within the past 4 weeks
* Solid tumor curated by chemotherapy or chest radiotherapy
* Chronic respiratory disease
* Asthma exacerbation within the past 3 months
* Oral or systemic corticotherapy within the past 3 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GILLES DEVOUASSOUX, Pr
Role: PRINCIPAL_INVESTIGATOR
Hospices Civils de Lyon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cabinets de Pneumologie Liberale
Caluire-et-Cuire, , France
Hospices Civils de Lyon
Lyon, , France
CABINETS DE PNEUMOLOGIE LIBERALE HIA Desgenettes
Lyon, , France
HC pneumo C
Pierre-Bénite, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL14_0212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.